#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14930	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2497	723.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1803	1803	T	973	T,C	971,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14930	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2497	723.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1537	1537	C	940	C,T	939,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14930	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2497	723.3	0	HET	.	.	.	G187A,T	.	187	187	G	540	540	G	915	G,A,T	537,376,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24896	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4217	737.3	0	.	n	.	0	T695C	SNP	695	695	T	1288	1288	C	903	C,T,G	901,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24896	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4217	737.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	2231	2231	G	934	G,A,C	932,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24896	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4217	737.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2564	2564	C	870	C,T	869,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24896	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4217	737.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2638	2638	A	827	A,C	825,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24896	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4217	737.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3190	3190	C	834	C,G	833,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	2174	folP	852	852	100.0	folP.l15.c4.ctg.1	2190	123.7	1	SNP	p	R228S	0	.	.	682	684	CGC	1390	1392	CGC	202;204;207	C,A;G;C	200,2;204;207	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5054	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4076	154.9	1	SNP	p	S91F	0	.	.	271	273	TCC	978	980	TCC	202;200;200	T;C,A;C	202;199,1;200	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5054	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4076	154.9	1	SNP	p	D95G	0	.	.	283	285	GAC	990	992	GAC	212;213;213	G;A,G;C,T	211;212,1;212,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5054	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4076	154.9	1	SNP	p	D95N	0	.	.	283	285	GAC	990	992	GAC	212;213;213	G;A,G;C,T	211;212,1;212,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1976	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1934	127.5	1	SNP	p	G45D	0	.	.	133	135	GGC	808	810	GGC	232;232;235	G,T;G;C	231,1;232;235	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1102	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1527	89.9	0	.	n	.	0	T10C	SNP	10	10	T	688	688	C	187	C	187	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1102	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1527	89.9	0	.	n	.	0	A197.	DEL	197	197	A	874	874	A	230	A	230	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1769	1771	ATC	197;198;196	A;T;C	197;198;196	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1922	1924	GCA	207;206;205	G,T;C;A	206,1;206;205	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2405	2407	ATT	197;196;193	A;T;T	196;195;192	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	1	SNP	p	D86N	0	.	.	256	258	GAC	875	877	GAC	205;205;206	G,A;A,C;C	203,2;204,1;206	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	1	SNP	p	S87I	0	.	.	259	261	AGT	878	880	AGT	205;205;208	A,G,C;G;T	202,2,1;205;208	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	1	SNP	p	S87W	0	.	.	259	261	AGT	878	880	AGT	205;205;208	A,G,C;G;T	202,2,1;205;208	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	1	SNP	p	S87R	0	.	.	259	261	AGT	878	880	AGT	205;205;208	A,G,C;G;T	202,2,1;205;208	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4550	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3487	162.9	1	SNP	p	S88P	0	.	.	262	264	TCC	881	883	TCC	210;211;213	T;C;C,T	210;211;212,1	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4078	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3186	159.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1785	1787	GGC	199;200;197	G,A;G;C,G	198,1;200;196,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1499	1501	GCA	276;275;274	G,A;C;A	275,1;275;274	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1502	1504	ATC	275;275;277	A;T,C;C	275;274,1;277	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1514	1516	GTG	270;271;268	G;T,G;G	270;270,1;268	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1514	1516	GTG	270;271;268	G;T,G;G	270;270,1;268	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2018	2020	ACC	251;252;251	A;C;C,T	251;252;249,2	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2072	2074	GCG	255;252;258	G;C,G;G	255;251,1;258	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2072	2074	GCG	255;252;258	G;C,G;G	255;251,1;258	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2195	2197	GGT	269;270;270	G;G;T	269;270;270	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2204	2206	GGC	265;268;267	G,A;G;C	264,1;268;267	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4616	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2877	200.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2222	2224	CCG	271;269;265	C;C;G	271;269;265	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5776	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3567	202.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1863	1865	CCG	241;241;244	C,T,G;C,T,G;G	239,1,1;239,1,1;244	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2172	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2338	116.1	0	.	p	.	0	S22G	NONSYN	64	66	AGC	661	663	GGC	150;148;147	G,A;G;C	148,2;148;147	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2172	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2338	116.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	843	843	C	153	C	153	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	S271A	NONSYN	811	813	TCG	96	98	GCT	80;80;80	G;C;T	80;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	102	104	GAT	80;80;80	G;A;T	80;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	105	107	AGT	80;80;80	A;G;T	80;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	N277H	NONSYN	829	831	AAC	114	116	CAC	80;80;80	C,G;A;C	79,1;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	R307E	NONSYN	919	921	AGA	204	206	GAA	6;6;6	G;A;A	6;6;6	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	216	218	GCA	6;6;6	G;C;A	6;6;6	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	219	221	GAC	6;6;6	G;A;C	6;6;6	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	225	227	ATC	6;6;6	A;T;C	6;6;6	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	231	233	TCG	7;7;7	T;C;G	7;7;7	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	237	239	GCC	7;7;7	G;C;C	7;7;7	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	240	242	AGC	7;7;7	A;G;C	7;7;7	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	243	245	GCC	7;7;7	G;C;C	7;7;7	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	364	porB1a	984	269	91.45	porB1a.l15.c30.ctg.2	398	34.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	249	251	GTT	6;6;6	G;T;T	6;6;6	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3068	porB1b	1047	1047	99.62	porB1b.l15.c17.ctg.1	2021	189.2	0	.	p	.	0	G120N	NONSYN	358	360	GGC	870	872	AAC	252;252;254	A;A,C;C	252;251,1;254	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3068	porB1b	1047	1047	99.62	porB1b.l15.c17.ctg.1	2021	189.2	1	SNP	p	D121N	1	D121N	NONSYN	361	363	GAC	873	875	AAC	254;258;260	A;A;C,G	254;258;259,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3068	porB1b	1047	1047	99.62	porB1b.l15.c17.ctg.1	2021	189.2	0	.	p	.	0	T292A	NONSYN	874	876	ACT	1386	1388	GCT	253;253;256	G;C,G;T	253;252,1;256	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10424	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5438	239.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2313	2315	CAT	265;260;259	C;A;T,G	265;260;258,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1588	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1655	119.9	1	SNP	p	V57M	1	.	.	169	171	ATG	809	811	ATG	273;273;275	A;T;G	273;273;275	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
